Recordati S.p.A. - Recordati licenses an immuno-suppressant drug for Italy, France and Spain

Press Releases

Recordati licenses an immuno-suppressant drug for Italy, France and Spain

Milan, 7 October 2002

Recordati announced today that it has acquired an exclusive license for the sale in Italy, France and Spain of a new oral formulation of cyclosporin from Dexcel Limited, a Dexxon Company, Israel. This is an important and well established immuno-suppressant drug which is indicated mainly to prevent rejection following organ transplants.

A European patent application for this novel oral formulation of cyclosporin is pending and filings for marketing approvals have been made in various European countries. The 2001 combined market value of this class of drugs in Italy, France and Spain amounts to approximately euro 150 million.

"The agreement with Dexcel strengthens the group's multi-territorial pipeline", declared Giovanni Recordati, Chairman and CEO. "This is the first product for which we have acquired the rights for the three countries where we have a direct presence in a single stroke. Cyclosporin is an important product which we believe will contribute to the consolidation of our future growth."

Dexcel is a prestigious international pharmaceutical company, which focuses on research, development and manufacturing of pharmaceutical products, based on Dexcel's Innovative Controlled Drug Delivery Technologies. Dexcel markets its Innovative Products by its affiliated companies in the US, UK and Germany, and by its licensees in other EU countries. Dexcel's state-of-the-art facility in Israel conforms to the highest cGMP requirements, approved by the US FDA, and EU Authorities. Dexcel's 550 employees will achieve annual sales value of $82M in 2002.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Portugal, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2002 Print Page Bookmark Page
Shareholder information Recordati at a glance Key Financial Data Recordati Share Press Releases 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Calendar Analyst Coverage Contacts	Press Releases Recordati licenses an immuno-suppressant drug for Italy, France and Spain Milan, 7 October 2002 Recordati announced today that it has acquired an exclusive license for the sale in Italy, France and Spain of a new oral formulation of cyclosporin from Dexcel Limited, a Dexxon Company, Israel. This is an important and well established immuno-suppressant drug which is indicated mainly to prevent rejection following organ transplants. A European patent application for this novel oral formulation of cyclosporin is pending and filings for marketing approvals have been made in various European countries. The 2001 combined market value of this class of drugs in Italy, France and Spain amounts to approximately euro 150 million. "The agreement with Dexcel strengthens the group's multi-territorial pipeline", declared Giovanni Recordati, Chairman and CEO. "This is the first product for which we have acquired the rights for the three countries where we have a direct presence in a single stroke. Cyclosporin is an important product which we believe will contribute to the consolidation of our future growth." Dexcel is a prestigious international pharmaceutical company, which focuses on research, development and manufacturing of pharmaceutical products, based on Dexcel's Innovative Controlled Drug Delivery Technologies. Dexcel markets its Innovative Products by its affiliated companies in the US, UK and Germany, and by its licensees in other EU countries. Dexcel's state-of-the-art facility in Israel conforms to the highest cGMP requirements, approved by the US FDA, and EU Authorities. Dexcel's 550 employees will achieve annual sales value of $82M in 2002. Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Portugal, Spain, Switzerland and the United States.